首页 | 本学科首页   官方微博 | 高级检索  
     


Ampicillin-Sulbactam versus Cefoxitin for Prophylaxis in High-Risk Patients Undergoing Abdominal Surgery
Authors:Dr. Joseph A. Paladino Pharm.D.  Dr. Miguel A. Rainstein M.D.   FACS  Mrs. Deborah J. Serrianne R.N.  Dr. John E. Przylucki M.D.   FACS  Dr. Lynda S. Welage Pharm.D.  Dr. Mario L. Collura M.D.   FACS  Dr. Jerome J. Schentag Pharm.D.   FCCP
Affiliation:1. Clinical Pharmacokinetics Laboratory

State University of New York at Buffalo, New York.;2. Department of Surgery, Millard Fillmore Hospitals

State University of New York at Buffalo, New York.

Abstract:This double-blind study compared ampicillin-sulbactam 3 g versus cefoxitin 2 g in 136 adult patients at risk for developing an infection after abdominal surgery. Separate randomization schedules were used for colorectal, upper gastrointestinal/biliary, and other abdominal procedures. Study antibiotics were administered within 30 minutes before incision and repeated 6 hours later. Patients having colorectal surgery received a third dose of antibiotic 6 hours after the second. Efficacy evaluations were made on 123 patients, 62 in the ampicillin-sulbactam group and 61 in the cefoxitin group. The overall postoperative infection rates were 12.9% for ampicillin-sulbactam and 9.8% for cefoxitin (p>0.05); one wound infection occurred in each group. Adverse events were experienced by 13.2% of the ampicillin-sulbactam and 19.1% of the cefoxitin recipients (p>0.05). Cost-minimization analysis revealed that ampicillin-sulbactam was a cost-effective alternative to cefoxitin for the prevention of infection after abdominal surgery.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号